Headquartered in Irvine, CA Fiscal year ends December NYSE: EW edwards.com
Edwards Lifesciences Corporation is a global structural heart innovation company focused on developing therapies for structural heart disease and critical care monitoring. The company's core business centers on transcatheter aortic valve replacement (TAVR) using its SAPIEN platform, transcatheter mitral and tricuspid therapies (TMTT) including the PASCAL repair system, EVOQUE tricuspid replacement system, and SAPIEN M3 mitral replacement system, as well as surgical heart valve therapies featuring its proprietary RESILIA tissue technology. Edwards serves patients with aortic stenosis, mitral regurgitation, and tricuspid regurgitation through minimally invasive and surgical approaches. The company previously divested its Critical Care business and now operates as a pure-play structural heart company. Edwards generates revenue across the United States, Europe, Japan, and the rest of the world, with a growing portfolio of clinical evidence supporting proactive disease management and earlier intervention in valve disease. Updated
Edwards Lifesciences (NYSE: EW | EW Price Prediction) and Boston Scientific (NYSE: BSX) both reported strong quarters, but the results reveal fundamentally different strategies in the heart device market. Edwards doubled down…
Pre-Market Futures: The futures are trading higher this morning after another stellar day across Wall Street on Tuesday, as all the major indices once again ended higher and continue to print new…
South Korea’s National Pension Fund (NPF) is the world’s third-largest pension fund by total assets. It manages 1,185.2 trillion South Korean won ($817 billion). NPF was created by the National Pension Service…
Wednesday's top analyst upgrades and downgrades included AMC Entertainment, Bumble, Comerica, Dell Technologies, Edwards Lifesciences, Etsy, Fisker, Luminar Technologies, Micron Technology, Opendoor Technologies, Pinterest and Snap.
Wednesday's top analyst upgrades and downgrades included Alphabet, Bank of America, Dollar General, Edwards Lifesciences, Fortinet, Fox, Halliburton, LyondellBasell Industries, Paramount Global, SoFi Technologies and Truist Financial.
Wednesday's top analyst upgrades and downgrades included Array Technologies, Conagra Brands, Costco Wholesale, Edwards Lifesciences, Estee Lauder, General Electric, General Mills, Hanesbrands, JPMorgan Chase, Lumen Technologies, Royal Caribbean Cruise, Schlumberger, State Street,…
Friday’s additional top analyst upgrades and downgrades were on Axalta Coating Systems, Caterpillar, DigitalOcean, Edwards Lifesciences, First Solar, Gilead Sciences, Intel, Stanley Black & Decker, Unity Software, Western Union and more.
Thursday's top analyst upgrades and downgrades included Abbott Laboratories, Biohaven, Edwards Lifesciences, Enphase Energy, Halliburton, Invesco, Liberty Energy, Mattel, Netflix, Permian Resources, Range Resources, Roblox, Synchrony Financial and Visa.
Wednesday's top analyst upgrades and downgrades included APA, Edwards Lifesciences, Enterprise Products Partners, Global Payments, International Paper, Johnson & Johnson, Match, Medtronic, Netflix, Trade Desk, UDR and Walmart.
Tuesday's top analyst upgrades and downgrades included Adobe, Cheniere Energy, CNX Resources, Edwards Lifesciences, EOG Resources, Huntsman, Kraft Heinz, NCR, Peloton Interactive, PulteGroup, Take-Two Interactive Software and UDR.
Wednesday afternoon's top analyst upgrades and downgrades included Acadia Pharmaceuticals, Constellation Energy, Edwards Lifesciences, Host Hotels & Resorts, Johnson & Johnson and Magna International.
Thursday's top analyst upgrades and downgrades included Advanced Micro Devices, Beyond Meat, Colgate-Palmolive, Edwards Lifesciences, Electronic Arts, Exxon Mobil, Meta Platforms, PayPal and Starbucks.
After a good start on Wednesday, markets sank in the afternoon. Thursday's opening was indicated to be mixed.
Thursday’s top analyst upgrades and downgrades included Airbnb, Citigroup, Edwards Lifesciences, Huntsman, KeyCorp, McDonald's, Netflix, Peloton, Southwest Airlines, Starbucks, Twitter, Under Armour, UPS and Walt Disney.
Thursday’s top analyst upgrades and downgrades included AutoZone, Charter Communications, Edwards Lifesciences, FuboTV, MFA Financial, Phillips 66, Southwest Airlines, Stitch Fix, TechnicFMC and Toll Brothers.
Edwards Lifesciences Corporation is a global structural heart innovation company focused on developing therapies for structural heart disease and critical care monitoring.
24/7 Wall St.'s 12-month price target for EW is $104.78, rated Buy. The Wall Street consensus target is $101.64. EW price prediction →
